Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke
Condition(s) studied
Investigational drug(s) / intervention(s)
Statins and/or Ezetimibe: Statin ± Ezetimibe to achieve target LDL-cholesterol level
PCSK9 inhibitor: The use of PCSK9 inhibitors is permitted to achieve target LDL-cholesterol levels in participants who did not reach the target with statins ± ezetimibe.
Study summary
Lipid-lowering therapy constitutes a cornerstone of secondary prevention in ischemic stroke; however, current stroke guidelines remain deficient in providing optimal target low-density lipoprotein (LDL)-cholesterol levels tailored to the stroke subtypes. Most clinical trials on LDL-cholesterol management have not differentiated between stroke subtypes or have primarily focused on large artery atherosclerosis (LAA) stroke, leaving a gap in evidence for managing LDL-cholesterol in other stroke subtypes, e.g., small vessel occlusion (SVO) stroke. While hypertension is the leading risk factor for SVO strokes, the link between elevated LDL-cholesterol and SVO stroke is also recognized. Establishing optimal LDL-cholesterol targets for SVO stroke would significantly enhance secondary prevention strategies and improve patient outcome. Thus, the investigators aim to compare intensive versus standard lipid-lowering in patients with SVO stroke. SVO70 is a multicenter, prospective, randomized, open, blinded-endpoint clinical trial. Adult participants with objectively confirmed SVO stroke within 180 days of randomization will be included. Exclusion criteria include those with predefined LDL-cholesterol targets for other conditions, baseline LDL-cholesterol \<70 mg/dL in the absence of lipid-lowering therapy, statin contraindications, or women who are pregnant, breastfeeding, or planning pregnancy during the study period. Eligible participants will be randomized 1:1 to target LDL-cholesterol \<70 mg/dL (intensive group) or 90-110 mg/dL (standard group). The trial plans to enroll 4,016 participants, with the primary outcome being major adverse cardiovascular events-cardiovascular death, stroke, and acute coronary syndrome-during a follow-up period of at least 4 years. This study would provide valuable information for determining the optimal LDL-cholesterol target for patients with SVO stroke.
Eligibility
Primary outcome measure(s)
- Major adverse cardiovascular event — 4 years
Major adverse cardiovascular event (MACE) includes cardiovascular death, stroke, and acute coronoary syndrome (i.e., ST-elevation myocardial infarction, non-ST elevation myocardial infarction, and unstable angina).
Trial sites (46)
| Facility | City | Region | Status |
|---|---|---|---|
| Korea University Ansan Hospital | Ansan | South Korea | Recruiting |
| Hallym University Sacred Heart Hospital | Anyang | South Korea | Recruiting |
| Pusan National University Hospital | Busan | South Korea | Recruiting |
| Gyeongsang National University Changwon Hospital | Changwon | South Korea | Recruiting |
| Samsung Changwon Hospital | Changwon | South Korea | Recruiting |
| Chungbuk National University Hospital | Cheongju-si | South Korea | Recruiting |
| Hallym University Chuncheon Sacred Heart Hospital | Chuncheon | South Korea | Recruiting |
| Kangwon National University Hospital | Chuncheon | South Korea | Recruiting |
| Daegu Catholic University Medical Center | Daegu | South Korea | Recruiting |
| Keimyung University Dongsan Medical Center | Daegu | South Korea | Recruiting |
| Kyungpook National University Chilgok Hospital | Daegu | South Korea | Recruiting |
| Kyungpook National University Hospital | Daegu | South Korea | Recruiting |
| Chungnam National University Hospital | Daejeon | South Korea | Recruiting |
| Daejeon Eulji Medical Center | Daejeon | South Korea | Recruiting |
| Dongguk University Ilsan Hospital | Goyang | South Korea | Withdrawn |
| Ilsan Paik Hospital | Goyang | South Korea | Recruiting |
| National Health Insurance Service Ilsan Hospital | Goyang | South Korea | Recruiting |
| Hanyang University Guri Hospital | Guri-si | South Korea | Recruiting |
| Chonnam National University Hospital | Gwangju | South Korea | Recruiting |
| Chosun University Hospital | Gwangju | South Korea | Withdrawn |
| Chung-Ang University Gwangmyeong Hospital | Gwangmyeong | South Korea | Recruiting |
| Dongtan Sacred Heart Hospital | Hwaseong | South Korea | Recruiting |
| Wonkwang University Hospital | Iksan | South Korea | Recruiting |
| Gachon University Gil Medical Center | Incheon | South Korea | Recruiting |
| Inha University Hospital | Incheon | South Korea | Recruiting |
| International St. Mary's Hospital | Incheon | South Korea | Withdrawn |
| Jeju National University Hospital | Jeju City | South Korea | Recruiting |
| Seoul National University Bundang Hospital | Seongnam | South Korea | Recruiting |
| Asan Medical Center | Seoul | South Korea | Recruiting |
| Chung-Ang University Hospital | Seoul | South Korea | Recruiting |
| Ewha Womans University Mokdong Hospital | Seoul | South Korea | Recruiting |
| Ewha Womans University Seoul Hospital | Seoul | South Korea | Recruiting |
| Gangnam Severance Hospital | Seoul | South Korea | Recruiting |
| Hallym University Kangdong Sacred Heart Hospital | Seoul | South Korea | Recruiting |
| Hanyang University Seoul Hospital | Seoul | South Korea | Recruiting |
| Konkuk University Medical Center | Seoul | South Korea | Recruiting |
| Korea University Anam Hospital | Seoul | South Korea | Recruiting |
| Kyung Hee University Medical Center | Seoul | South Korea | Recruiting |
| National Medical Center | Seoul | South Korea | Recruiting |
| Nowon Eulji Medical Center | Seoul | South Korea | Recruiting |
+ 6 more sites — see the full list on the official registry below.
More Seoul National University Hospital trials in South Korea
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06649240 on ClinicalTrials.gov ↗ ← All trials in South Korea